The evolving landscape of tissue‐agnostic therapies in precision oncology

Vivek Subbiah(The University of Texas MD Anderson Cancer Center), Razelle Kurzrock(Medical College of Wisconsin), Bettina Ryll(Stockholm School of Economics), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Howard A. Burris(Marqués de Valdecilla University Hospital)
CA A Cancer Journal for Clinicians
May 30, 2024
10.3322/caac.21844
Cited by 68

Related Papers

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k